Disclosed positions

Estimated from their latest filings — positions may have changed since

$815.5K

combined est. value

Stock	Shares	Price	Value	Weight	As of
AGIOAGIOS PHARMACEUTICALS, INC.	15,230	$31.72	$483.1K	59%	2026-06-18
AKBAAkebia Therapeutics, Inc.	160,933	$1.40	$225.3K	28%	2025-06-10
SPROSpero Therapeutics, Inc.	85,000	$1.26	$107.1K	13%	2026-06-23

AGIO

AGIOS PHARMACEUTICALS, INC.

$483.1K

15,230 sh

AKBA

Akebia Therapeutics, Inc.

$225.3K

160,933 sh

SPRO

Spero Therapeutics, Inc.

$107.1K

85,000 sh

All filings on record

Every Form 4 transaction we track for this filer

all 6buys 0sells 0

Stock	Transaction	Date	~6mo later
SPROSpero Therapeutics, Inc.	Grant — · 10,000 sh	2026-06-23	—
AGIOAGIOS PHARMACEUTICALS, INC.	Exercise — · 2,816 sh	2026-06-18	—
AGIOAGIOS PHARMACEUTICALS, INC.	Exercise — · 2,302 sh	2025-08-11	—
AGIOAGIOS PHARMACEUTICALS, INC.	Exercise — · 2,120 sh	2025-06-20	—
SPROSpero Therapeutics, Inc.	Grant — · 20,000 sh	2025-06-12	—
AKBAAkebia Therapeutics, Inc.	Grant — · 35,700 sh	2025-06-10	—

SPROGrant

2026-06-23 · Spero Therapeutics, Inc.

10,000

—

AGIOExercise

2026-06-18 · AGIOS PHARMACEUTICALS, INC.

2,816

—

AGIOExercise

2025-08-11 · AGIOS PHARMACEUTICALS, INC.

2,302

—

AGIOExercise

2025-06-20 · AGIOS PHARMACEUTICALS, INC.

2,120

—

SPROGrant

2025-06-12 · Spero Therapeutics, Inc.

20,000

—

AKBAGrant

2025-06-10 · Akebia Therapeutics, Inc.

35,700

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.